Nanoparticular delivery system for a secretoneurin derivative induces angiogenesis in a hind limb ischemia model

• DOI: 10.1016/j.jconrel.2017.02.004
• Publication Date: 2017-02-04T07:15:36Z
• Authors: Karin Albrecht-Sc...; Jan Barthelmes; Wilfried Schgoer; Markus Theurl; Isabelle Nardin; Daniela Lener; Clemens Gutmann; Sarah Dünnhaupt; Andreas Bernkop-S...; Rudolf Kirchmair
• Keywords: 0301 basic medicine; Chitosan; Neuropeptides; Neovascularization, Physiologic; Apoptosis; Hindlimb; 3. Good health; Mice; Peripheral Arterial Disease; 03 medical and health sciences; Drug Delivery Systems; Ischemia; Secretogranin II; Human Umbilical Vein Endothelial Cells; Animals; Humans; Nanoparticles; Angiogenesis Inducing Agents; Endothelium, Vascular; Particle Size; Muscle, Skeletal; Chromatography, High Pressure Liquid; Cell Proliferation

Common therapeutic strategies for peripheral arterial disease often fail to re-establish sufficient blood flow within legs and feet of patients for avoiding critical limb ischemia, what is characterized by a substantial risk for amputation. The neuropeptide secretoneurin induces angiogenesis in models of limb and myocardial ischemia and might be a promising tool in the treatment of patients without the option of revascularization therapy for severe ischemia. Within this manuscript, the biologically active part of secretoneurin was identified, modified by induction of a cysteine residue to gain higher stability against enzymatic degradation and further packed into S-protected thiolated chitosan nanoparticles, which enable intra-muscular application of secretoneurin. Secretoneurin nanoparticles restored blood flow in a mouse hind limb ischemia model within one week, whereas control particles did not. In vitro testing also revealed the angiogenic, antiapoptotic and proliferative effects of the new secretoneurin derivate, as tested in primary human umbilical vein endothelial cells. With the work from this study we provide a new promising tool for treatment of peripheral arterial disease.